Cost-Effectiveness Analysis of Daridorexant for the Pharmacological Treatment of Chronic Insomnia Disorder in Adults
Daridorexant 50 mg is estimated to be a cost-effective pharmacological treatment for chronic insomnia disorder in adult patients.
Authors
- Benjamin N. Greenwood (ORCID: https://orcid.org/0000-0002-4630-3205)
- Andrew Briggs (ORCID: https://orcid.org/0000-0002-0777-1997)
- Charles M. Morin (ORCID: https://orcid.org/0000-0002-8649-8895)
- François-Xavier Chalet (ORCID: https://orcid.org/0000-0002-2178-8920)
- Andrew Walker (ORCID: https://orcid.org/0000-0003-1128-8954)
- Jacie Cooper (ORCID: https://orcid.org/0000-0001-8456-7589)
- P.M. Graham (ORCID: https://orcid.org/0000-0002-3955-7020)
- Paul W. Miller (ORCID: https://orcid.org/0000-0002-8441-4109)
- Stephen Palmer
Institutions
- London School of Hygiene & Tropical Medicine (GB)
- Idorsia (Switzerland) (CH)
- Avalon Pharma (United States) (US)
- Université Laval (CA)
- University of York (GB)
Publication Details
- Journal
- PharmacoEconomics - Open
- Published
- 2025-03-28
- DOI
- https://doi.org/10.1007/s41669-025-00567-1
- Citations
- 3
- Primary Topic
- Sleep and related disorders
- Type
- article
- Field-Weighted Citation Impact
- 6.35
Funders
- Idorsia Pharmaceuticals